AbbVie shared results from the ECOG-ACRIN Cancer Research Group, National Cancer Institute-sponsored, Phase 3 study evaluating Imbruvica plus rituximab versus the current National Comprehensive Cancer Network guidelines Category 1 treatment of fludarabine, cyclophosphamide and rituximab in previously untreated younger patients with chronic lymphocytic leukemia, CLL, and small lymphocytic lymphoma, SLL. This interim analysis showed that Imbruvica plus rituximab significantly prolonged progression-free survival, the primary endpoint of the study, compared to FCR, with a 65% reduction in risk of progression or death. Furthermore, Imbruvica plus rituximab significantly improved overall survival compared to FCR. The findings were presented today during the Late-Breaker abstract oral session at the 2018 American Society of Hematology, or ASH, Annual Meeting.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.